Skip to main content

3 Result(s)

within Helena Harlin Remove this filter

and

  1. No Access

    Article

    Prognostic significance of tumor iNOS and COX-2 in stage III malignant cutaneous melanoma

    New prognostic markers are needed for malignant melanoma. Inducible nitric oxide synthase (iNOS) and cyclooxygenase type 2 (COX-2) have been described to correlate with progression of melanoma. Moreover, activ...

    C. Christian Johansson, Suzanne Egyházi… in Cancer Immunology, Immunotherapy (2009)

  2. No Access

    Article

    Tumor progression despite massive influx of activated CD8+ T cells in a patient with malignant melanoma ascites

    Although melanoma tumors usually express antigens that can be recognized by T cells, immune-mediated tumor rejection is rare. In many cases this is despite the presence of high frequencies of circulating tumor...

    Helena Harlin, Todd V. Kuna, Amy C. Peterson, Yuru Meng… in Cancer Immunology, Immunotherapy (2006)

  3. No Access

    Article

    A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma

    Purpose: Bryostatin-1 is a PKC modulator with direct anti-tumor activity and immunomodulatory properties. We combined different doses of Bryostatin-1 with IL-2 to determine effects on cli...

    Amy C. Peterson, Helena Harlin, Theodore Karrison… in Investigational New Drugs (2006)